Sodium

Longitudinal Data

Trend Analysis

The November 2022 sodium value of 132 mmol/L establishes that mild hyponatremia was present 3 years before AML diagnosis and before Aza-Ven treatment. This changes the interpretation: hyponatremia is not purely a treatment-related or AML-related phenomenon. The SIADH workup remains outstanding but becomes more urgent given this chronic pattern.

Sodium was normal (136-139 mmol/L) through July 2025 and into mid-January 2026. Beginning late January 2026, a persistent mild hyponatremia developed, with values consistently in the 132-135 range. A previous nadir of 129 mmol/L was reached on 2026-03-12. On 2026-04-20, sodium dropped to a new nadir of 128 mmol/L — moderate hyponatremia. Sodium then improved to 134 mmol/L on Apr 27, and as of 2026-05-04, sodium has normalized to 142 mmol/L — within normal range (136–145) for the first time since January 2026. This represents a complete resolution of the hyponatremic episode over two weeks (+8 mmol/L from Apr 27, +14 mmol/L from Apr 20 nadir).

[!info] Sodium Normalized — 134 → 142 mmol/L (Apr 27 → May 4)
Sodium has normalized to 142 mmol/L — within reference range (136–145) for the first time since mid-January 2026. The two-week trajectory: 128 (Apr 20 nadir) → 134 (Apr 27, still low) → 142 (May 4, normal). Concurrent chloride also normalized (103 mmol/L), consistent with overall electrolyte stabilization. Magnesium also normalized to 1.6 mg/dL (lower limit of normal). See Hyponatremia, Magnesium, Chloride.

[!info] SIADH Workup Still Needed
Although sodium has normalized, the etiology of the Jan–Apr 2026 hyponatremia remains unexplained. SIADH workup (urine osm, urine Na) has never been done. The fact that hyponatremia predates AML (132 in Nov 2022) suggests a chronic non-treatment-related etiology. Consider workup if hyponatremia recurs. See Hyponatremia.